Nonalcoholic Fatty Liver Disease After Liver Transplantation for Cryptogenic Cirrhosis or Nonalcoholic Fatty Liver Disease

被引:176
|
作者
Yalamanchili, Kanthi [1 ,2 ,3 ]
Saadeh, Sherif [1 ,2 ]
Klintmalm, Goeran B. [1 ,2 ]
Jennings, Linda W. [1 ,2 ]
Davis, Gary L. [1 ,2 ]
机构
[1] Baylor Univ, Med Ctr, Dept Med, Dallas, TX 75246 USA
[2] Baylor Univ, Med Ctr, Baylor Reg Transplant Inst, Dept Surg, Dallas, TX 75246 USA
[3] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA
关键词
NATURAL-HISTORY; HEPATOCELLULAR-CARCINOMA; STEATOHEPATITIS; PREVALENCE; SURVIVAL; SPECTRUM; OBESITY; RISK;
D O I
10.1002/lt.22004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples were assessed for steatosis and fibrosis. Two hundred fifty-seven patients (12%) had a pretransplant diagnosis of cryptogenic cirrhosis (239) or NASH (18). Fatty liver developed in 31% and was more common when the pretransplant diagnosis was NASH (45% at 5 years versus 23% for cryptogenic cirrhosis, P = 0.007). NASH developed in only 4% and occurred exclusively when steatosis had already occurred. Steatosis after liver transplantation was associated with the baseline body weight and body mass index by univariate analyses, but no pretransplant or posttransplant characteristic independently predicted steatosis after liver transplantation because obesity was so common in all groups. Five percent and 10% developed bridging fibrosis or cirrhosis after 5 and 10 years, respectively, and this was more common after NASH (31%) than in those who developed steatosis alone (6%) or had no fat (3%, P = 0.002). One-, 5-, and 10-year survival was the same in patients who underwent transplantation for cryptogenic cirrhosis or NASH (86%, 71%, and 56%) and in patients who underwent transplantation for other indications (86%, 71%, and 53%; not significant), but death was more often due to cardiovascular disease and less likely from recurrent liver disease. In conclusion, fatty liver is common after liver transplantation for cryptogenic cirrhosis or NASH but is twice as common in the latter group; this suggests that some cryptogenic cirrhosis, but perhaps not all, is caused by NASH. Posttransplant NASH is unusual, and steatosis appears to be a prerequisite. Advanced fibrosis is uncommon, and survival is the same as that of patients who undergo transplantation for other causes. Liver Transpl 16:431-439, 2010. (C) 2010 AASLD.
引用
收藏
页码:431 / 439
页数:9
相关论文
共 50 条
  • [21] Nonalcoholic fatty liver disease
    Alfie, ME
    Treem, WR
    PEDIATRIC ANNALS, 2006, 35 (04): : 290 - +
  • [22] Nonalcoholic fatty liver disease
    Bayard, Max
    Holt, Jim
    Boroughs, Eileen
    AMERICAN FAMILY PHYSICIAN, 2006, 73 (11) : 1961 - 1968
  • [23] Nonalcoholic fatty liver disease
    Clark, JM
    Brancati, FL
    Diehl, AM
    GASTROENTEROLOGY, 2002, 122 (06) : 1649 - 1657
  • [25] Nonalcoholic Fatty Liver Disease
    Wang, Xiao Jing
    Malhi, Harmeet
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (09) : ITC65 - ITC80
  • [26] Nonalcoholic Fatty Liver Disease
    Sweet, Patrick H.
    Khoo, Teresa
    Nguyen, Steven
    PRIMARY CARE, 2017, 44 (04): : 599 - +
  • [27] Nonalcoholic Fatty Liver Disease
    Fitzgerald, Margaret A.
    NURSE PRACTITIONER, 2007, 32 (02): : 6 - 7
  • [28] Nonalcoholic fatty liver disease
    Elizabeth M. Brunt
    Vincent W.-S. Wong
    Valerio Nobili
    Christopher P. Day
    Silvia Sookoian
    Jacquelyn J. Maher
    Elisabetta Bugianesi
    Claude B. Sirlin
    Brent A. Neuschwander-Tetri
    Mary E. Rinella
    Nature Reviews Disease Primers, 1
  • [29] Nonalcoholic fatty liver disease
    Madan, P
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (07) : 734 - 735
  • [30] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    NATURE REVIEWS DISEASE PRIMERS, 2015, 1